{"id":"NCT03968159","sponsor":"ACADIA Pharmaceuticals Inc.","briefTitle":"Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment","officialTitle":"Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment (ACP-103-054/059)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-25","primaryCompletion":"2020-04-30","completion":"2020-05-29","firstPosted":"2019-05-30","resultsPosted":"2021-11-17","lastUpdate":"2021-11-17"},"enrollment":298,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Adjunctive Treatment of Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"Pimavanserin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Drug - pimavanserin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of adjunctive pimavanserin compared to placebo in subjects with major depressive disorder who have an inadequate response to antidepressant therapy","primaryOutcome":{"measure":"Change From Baseline to Week 5 in Hamilton Depression Scale (17 Items) (HAMD-17) Total Score","timeFrame":"Baseline, Week 5","effectByArm":[{"arm":"Pimavanserin","deltaMin":-9,"sd":0.58},{"arm":"Placebo","deltaMin":-8.1,"sd":0.58}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2956"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":85,"countries":["United States","Finland","Poland","Russia","Serbia","Slovakia","South Africa","Ukraine","United Kingdom"]},"refs":{"pmids":["36339271"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":148},"commonTop":["Headache","Diarrhoea","Dry mouth","Nasopharyngitis"]}}